TG Therapeutics Inc (TGTX.OQ)
TGTX.OQ on NASDAQ Stock Exchange Capital Market
14.40USD
20 Apr 2018
14.40USD
20 Apr 2018
Change (% chg)
$-0.30 (-2.04%)
$-0.30 (-2.04%)
Prev Close
$14.70
$14.70
Open
$14.70
$14.70
Day's High
$14.75
$14.75
Day's Low
$14.35
$14.35
Volume
135,625
135,625
Avg. Vol
287,871
287,871
52-wk High
$17.30
$17.30
52-wk Low
$7.25
$7.25
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2017 | Dec '17 | 0.04 | -0.463 |
| Sep '17 | 0.04 | -0.485 | |
| Jun '17 | 0.04 | -0.448 | |
| Mar '17 | 0.04 | -0.522 | |
| FY 2016 | Dec '16 | 0.04 | -0.480 |
| Sep '16 | 0.04 | -0.505 | |
| Jun '16 | 0.04 | -0.326 | |
| Mar '16 | 0.04 | -0.283 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 5 | 0.03 | 0.04 | 0.00 | 0.04 |
| Quarter Ending Sep-18 | 5 | 0.03 | 0.04 | 0.00 | 0.04 |
| Year Ending Dec-18 | 6 | 0.10 | 0.16 | 0.00 | 3.87 |
| Year Ending Dec-19 | 5 | 12.38 | 19.00 | 0.00 | 28.66 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 6 | -0.43 | -0.35 | -0.47 | -0.41 |
| Quarter Ending Sep-18 | 6 | -0.42 | -0.32 | -0.49 | -0.41 |
| Year Ending Dec-18 | 6 | -1.70 | -1.20 | -1.93 | -1.42 |
| Year Ending Dec-19 | 5 | -1.96 | -1.66 | -2.10 | -1.14 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 84.02 | 32.74 | |
| P/E High - Last 5 Yrs. | -- | 293.18 | 45.72 | |
| P/E Low - Last 5 Yrs. | -- | 91.59 | 24.22 | |
| Beta | 1.34 | 0.90 | 0.88 | |
| Price to Sales (TTM) | 5,555.65 | 110.89 | 5.71 | |
| Price to Book (MRQ) | 10.74 | 13.58 | 5.37 | |
| Price to Tangible Book (MRQ) | 10.97 | 14.04 | 6.95 | |
| Price to Cash Flow (TTM) | -- | 71.40 | 23.32 | |
| % Owned Institutions | 57.66 | 12.75 | 2.17 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.31 | 1.50 | |
| Dividend Yield - 5 Year Avg | -- | 0.26 | 1.51 | |
| Dividend 5 Year Growth Rate | -- | 1.66 | 5.32 | |
| Payout Ratio(TTM) | -- | 15.72 | 43.29 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 0.00 | 399.08 | 9.21 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 0.00 | 78.82 | 5.69 | |
| Sales - 5 Yr. Growth Rate | -- | 32.16 | 10.32 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -37.42 | 25.00 | 19.36 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -55.17 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 38.99 | 10.76 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 40.29 | 15.47 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 1.80 | 2.19 |
| Current Ratio (MRQ) | 4.67 | 5.30 | 2.98 |
| LT Debt to Equity (MRQ) | 0.00 | 22.96 | 12.18 |
| Total Debt to Equity (MRQ) | 0.20 | 24.62 | 16.45 |
| Interest Coverage (TTM) | -- | -99.35 | 32.81 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 40.02 | 54.44 | |
| Gross Margin - 5 Yr. Avg. | -- | 51.13 | 52.20 | |
| EBITD Margin (TTM) | -68,874.41 | -- | -- | |
| EBITD - 5 Yr. Avg | -38,777.75 | -574.75 | 10.96 | |
| Operating Margin (TTM) | -68,927.37 | -718.53 | 4.73 | |
| Operating Margin - 5 Yr. Avg. | -39,411.89 | -596.06 | 6.40 | |
| Pre-Tax Margin (TTM) | -68,625.83 | -693.00 | 5.57 | |
| Pre-Tax Margin - 5 Yr. Avg. | -38,709.13 | -599.42 | 6.81 | |
| Net Profit Margin (TTM) | -68,625.83 | -694.22 | 1.87 | |
| Net Profit Margin - 5 Yr. Avg. | -38,761.63 | -602.27 | 3.09 | |
| Effective Tax Rate (TTM) | -- | 22.62 | 23.04 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 18.21 | 23.96 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 2,381 | 22,626,821 | 846,830,978 | |
| Net Income/Employee (TTM) | -1,634,153 | 2,971,371 | 99,616,195 | |
| Receivable Turnover (TTM) | 1.72 | 20.16 | 5.78 | |
| Inventory Turnover (TTM) | -- | 2.37 | 3.35 | |
| Asset Turnover (TTM) | 0.00 | 0.39 | 0.92 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -106.72 | -1.11 | 10.95 | |
| Return on Assets - 5 Yr. Avg. | -79.87 | -0.57 | 12.31 | |
| Return on Investment (TTM) | -129.83 | 1.58 | 14.38 | |
| Return on Investment - 5 Yr. Avg. | -89.70 | 2.21 | 16.10 | |
| Return on Equity (TTM) | -133.51 | 2.41 | 16.07 | |
| Return on Equity - 5 Yr. Avg. | -90.58 | 3.09 | 17.39 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 0.00 | 0.00 | -- |
| EPS (TTM) % | -15.71 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for TG Therapeutics Inc
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-TG Therapeutics Announces Updated Results From The Ongoing Phase 2 Study Of Ublituximab
- BRIEF-TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies
- BRIEF-TG Therapeutics Announces Initiation Of Randomized Phase II Trial In Follicular Lymphoma
- BRIEF-TG Therapeutics qtrly net loss per common share $0.48
- BRIEF-TG Therapeutics Inc gives results from phase 2 multicenter trial of TG-1101
Institutional Holders
| % Shares Owned: | 54.48% |
| # of Holders: | 154 |
| Total Shares Held: | 41,177,350 |
| 3 Mo. Net Change: | 107,979 |
| # New Positions: | 6 |
| # Closed Positions: | 2 |
| # Increased Positions: | 14 |
| # Reduced Positions: | 8 |
| # Net Buyers: | 6 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.